Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
241.00M | 221.00M | 217.00M | 197.00M | 336.40M | Gross Profit |
170.00M | 170.00M | 168.00M | 146.00M | 123.00M | EBIT |
5.70B | 4.73B | -9.25B | 6.36B | 3.25B | EBITDA |
5.74B | 4.75B | -9.24B | 6.36B | 3.29B | Net Income Common Stockholders |
5.74B | 4.75B | -9.24B | 6.35B | 3.29B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
782.00M | 1.58B | 532.00M | 459.00M | 1.55B | Total Assets |
24.74B | 19.19B | 14.64B | 24.00B | 17.93B | Total Debt |
3.00M | 3.00M | 3.00M | 4.00M | 58.70M | Net Debt |
-643.00M | -1.45B | -413.00M | -322.00M | -1.20B | Total Liabilities |
52.00M | 57.00M | 95.00M | 48.00M | 232.30M | Stockholders Equity |
24.68B | 19.12B | 14.54B | 23.94B | 17.68B |
Cash Flow | Free Cash Flow | |||
172.00M | 1.37B | 160.00M | 958.00M | 37.00M | Operating Cash Flow |
172.00M | 1.37B | 176.00M | 980.00M | 59.30M | Investing Cash Flow |
-778.00M | -124.00M | 39.00M | -1.67B | -432.60M | Financing Cash Flow |
-201.00M | -206.00M | -125.00M | -151.00M | 940.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | kr6.61B | 32.47 | 16.42% | ― | 10.18% | -1.08% | |
72 Outperform | kr13.27B | 27.51 | 4.06% | 3.37% | -5.70% | -62.59% | |
70 Neutral | €21.65B | 186.64 | 0.27% | 0.91% | 13.61% | -97.82% | |
64 Neutral | $12.85B | 9.81 | 7.59% | 16985.65% | 12.30% | -7.71% | |
64 Neutral | kr6.23B | 14.16 | 7.27% | 2.80% | ― | ― | |
56 Neutral | kr22.88B | ― | ― | -95.90% | 27.54% | ||
54 Neutral | €19.45B | 753.59 | 0.16% | 0.83% | -3.94% | -94.09% |
Bure Equity AB reported a challenging first quarter in 2025, with a notable decline in net asset value and share performance. The company’s net asset value per share decreased by 10.7% from the beginning of the year, while the total return on Bure shares fell by 15.3%. The market turbulence was largely attributed to the new US administration’s foreign and trade policies, which introduced increased tariffs and impacted global financial markets. Despite the downturn, some portfolio companies like Mycronic and BioLamina showed strong performance, highlighting resilience amidst uncertainty. The CEO emphasized the importance of stable global trade for economic growth and expressed hope for pragmatic solutions to stabilize the market.
At the Annual General Meeting of Bure Equity AB held on May 8, 2025, several key decisions were made, including the approval of financial statements for 2024, a cash dividend of SEK 2.75 per share, and the re-election of the Board of Directors. The meeting also authorized the Board to repurchase shares and issue new shares to adjust the company’s capital structure, and approved a long-term incentive program to align employee and shareholder interests.